Valuation: Celcuity Inc.

Market Cap 389.69Cr 343.66Cr 325.04Cr 294.62Cr 552.94Cr 37TCr 557.9Cr 3.89TCr 1.5TCr 19TCr 1.46TCr 1.43TCr 61TCr P/E 2026 *
-16.1x
P/E 2027 * -47.9x
Enterprise Value 389.69Cr 343.66Cr 325.04Cr 294.62Cr 552.94Cr 37TCr 557.9Cr 3.89TCr 1.5TCr 19TCr 1.46TCr 1.43TCr 61TCr EV / Sales 2026 *
113x
EV / Sales 2027 * 11x
Free-Float
89.77%
Yield 2026 *
-
Yield 2027 * -
1 day-2.84%
1 week-7.88%
Current month-13.11%
1 month-12.51%
3 months-22.58%
6 months-27.01%
Current year-22.42%
1 week 77.07
Extreme 77.07
85.05
1 month 77.07
Extreme 77.07
98
Current year 77.07
Extreme 77.07
151.02
1 year 44.42
Extreme 44.42
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 01/01/2012
Chief Executive Officer 64 01/01/2012
Director of Finance/CFO 59 01/07/2017
Director TitleAgeSince
Chairman 64 01/01/2012
Director/Board Member 64 01/01/2012
Director/Board Member 67 01/02/2014
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/26 Free

Chief Financial Officer

26,000 0.0562%
14/08/26 Free

Founder

30,000 0.0648%
14/08/26 Free

Chief Executive Officer

2,00,000 0.4322%
Change 5-day change 1-year change 3-year change Capi.($)
-2.84%-7.88%+52.92%+723.19% 389.69Cr
-0.70%-4.35%+56.10%+86.42% 7.18TCr
+0.45%-2.26%+38.36%+87.74% 6.01TCr
+0.19%+0.94%+36.97%+21.32% 2.79TCr
-1.73%-4.44%-15.62%+348.87% 2.57TCr
-0.51%+0.58%+0.50%-3.39% 2.49TCr
+0.65%+2.52%+25.89%-6.99% 2.09TCr
+3.46%+3.91%+158.90%+337.81% 1.5TCr
+0.48%+2.50%+50.23%+161.95% 1.45TCr
+3.91%-4.56%-2.71%+506.41% 1.39TCr
Average +0.34%-0.06%+40.15%+226.33% 2.79TCr
Weighted average by Cap. +0.15%-0.53%+38.78%+136.66%

Financials

2026 *2027 *
Net sales 3.44Cr 3.03Cr 2.87Cr 2.6Cr 4.88Cr 329.74Cr 4.92Cr 34Cr 13Cr 168.35Cr 13Cr 13Cr 540.65Cr 35Cr 31Cr 30Cr 27Cr 50Cr 3.41TCr 51Cr 353.96Cr 136.53Cr 1.74TCr 133.25Cr 130.34Cr 5.58TCr
Net income -27Cr -23Cr -22Cr -20Cr -38Cr -2.55TCr -38Cr -265.13Cr -102.27Cr -1.3TCr -100Cr -98Cr -4.18TCr -8.68Cr -7.66Cr -7.24Cr -6.57Cr -12Cr -833.45Cr -12Cr -87Cr -33Cr -425.51Cr -33Cr -32Cr -1.37TCr
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
29/26/29 $77.38 -2.84% 7,90,250
28/26/28 $79.64 +0.15% 6,10,352
25/26/25 $79.52 +0.19% 6,57,167
24/26/24 $79.37 -0.78% 12,37,796
23/26/23 $79.99 -4.89% 7,39,444
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
79.64USD
Average target price
160.75USD
Spread / Average Target
+101.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock